A COVID-19 vaccine candidate developed at the University of Copenhagen has been approved for phase 1 testing on humans.
The vaccine is developed by a team of researchers at the University of Copenhagen in collaboration with the companies AdaptVac, ExpreS2ion Biotechnologies and Bavarian Nordic. The vaccine candidate, ABNCoV2, has now been approved for human clinical testing.
“Our vaccine candidate is characterized in that it elicits a strong immune response in animals. We hope and believe that the strong immune response both results in effective and long-lasting protection,” says Professor Ali Salanti.
“We hope the vaccine will be ready by the end of 2021 or beginning of 2022.”
In January this year, the researchers from the Department of Immunology and Microbiology at the Faculty of Health and Medical Sciences at UCPH published the results of the effect of the vaccine. They showed that one dosage of ABNCoV2 is very efficient. And two vaccinations resulted in an unprecedented high immune response.
“If the results of the clinical test are just as promising as we expect them to be, we hope the vaccine will be ready by the end of 2021 or beginning of 2022,” says Associate Professor Morten Agertoug Nielsen.
The researchers have also developed the technology on which ABNCoV2 is based. The technology is called cVLP, which is short for ‘capsid virus-like particle’. It is a particle mimicking a virus, but it is completely harmless. By closely combining antigens from the corona virus, SARS-CoV-2, which results in COVID-19, on the surface of the harmless virus copy and ’injecting’ the body with the harmless virus, the researchers are able to trick the body’s immune system into creating a strong response to the antigens. This teaches the body to recognize the SARS-CoV-2 virus as something dangerous, and it therefore produces large amounts of antibodies against this particular virus. The vaccine design follows the same principle as the HPV vaccine. It provokes a strong immune response in animals, that is, protection against the virus. The researchers hope for a so-called ‘full response’, which prevents the virus completely from entering the body.
“It may also be able to create a very long-lasting response, which means that you will be immune to the virus for a long time period, perhaps for years, but we will not know for certain until we have tested it on humans.”
“If the virus is unable to enter the body, it is unable to mutate, which of course is vital in fighting this virus,” says Associate Professor Adam Sander. “Aside from the fact that our vaccine elicits this extremely strong immune response, it may also be able to create a very long-lasting response, which means that you will be immune to the virus for a long time period, perhaps for years, but we will not know for certain until we have tested it on humans.”
The researchers expect that the vaccine can be stored at refrigerator temperature.
The clinical trials
Radhoud University Medical Centre in the Netherlands is responsible for the clinical trials, and the recruitment of test subjects has already begun. The first subjects will be given two vaccines one month apart, and they will then be monitored closely to assess immune responses and identify potential side effects.
The Prevent nCoV project
The vaccine, ABNCoV2, was developed at the University of Copenhagen within the Prevent nCoV project. It will be produced by AGC Biologics. The vaccine has been tested on rabbits in accordance with the rules in force regarding side effects.
The research is funded by the Carlsberg Foundation, the Independent Research Fund Denmark, Horizon 2020 and Gudbjørg and Ejnar Honoré’s Foundation.
Source: the University of Copenhagen. Photo of Ali Salanti. Photographer: Kristian Brasen